Skip to main content

Metformin Decelerates Aging and Development of Mammary Tumors in HER-2/neu Transgenic Mice


Transgenic FVB/N female mice carrying HER-2/neu mammary cancer gene received metformin (1200 mg/liter) with drinking water 5 days a week starting from the age of 2 months until natural death. Metformin slightly reduced food consumption, but did not change water consumption and dynamics of weight gain. Mean life span of mice increased by 8% (p<0.05), in 10% long-living mice it was prolonged by 13.1%, and the maximum life span was prolonged by 1 month under the effect of metformin in comparison with the control. The rate of populational aging decreased by 2.26 times. The total incidence of mammary adenocarcinoma and their multiplicity did not change under the effect of metformin, while the latency of tumor development increased and the mean diameter of tumors decreased. Hence, we first demonstrated a geroprotective effect of metformin and its suppressive effect towards the development of mammary tumors.

This is a preview of subscription content, access via your institution.


  1. 1.

    V. N. Anisimov, Molecular and Physiological Mechanisms of Aging [in Russian], St. Petersburg (2003).

  2. 2.

    L. M. Bershtein, Oncoendocrinology. Traditions, State of the Art, Prospects [in Russian], St. Petersburg (2004).

  3. 3.

    A. I. Bozhkov, Uspekhi Gerontol., 8, 89–99 (2001).

    Google Scholar 

  4. 4.

    E. V. Gubler, Computation Methods of Analysis and Recognition of Pathological Processes [in Russian], Leningrad (1978).

  5. 5.

    V. N. Anisimov, Exp. Gerontol., 38, No.10, 1041–1049 (2003).

    Article  PubMed  Google Scholar 

  6. 6.

    V. V. Bakaev, Biogerontology, 3,Suppl. 1, 23–24 (2002).

    Google Scholar 

  7. 7.

    D. R. Cox and D. Oakes, Analysis of Survival Data, London (1996).

  8. 8.

    V. M. Dilman and V. N. Anisimov, Gerontology, 26, No.5, 241–245 (1980).

    PubMed  Google Scholar 

  9. 9.

    V. M. Dilman, L. M. Bershtein, M. A. Zabezhinski, et al., Arch. Geschwulforsch., 48, No.1, 1–8 (1978).

    Google Scholar 

  10. 10.

    F. S. Facchini, N. W. Hua, G. M. Reaven, and R. A. Stoohs, Free Radic. Biol. Med., 29, No.12, 1302–1306 (2000).

    Article  PubMed  Google Scholar 

  11. 11.

    E. J. Masoro, Exp. Gerontol., 35, 299–305 (2000).

    Article  PubMed  Google Scholar 

  12. 12.

    M. N. Pollak, E. S. Schernhammer, and S. E. Hankinson, Nat. Rev. Cancer, 4, No.7, 505–518 (2004).

    Article  PubMed  Google Scholar 

  13. 13.

    S. R. Spindler, J. D. Dhahbi, P. L. Mote, et al., Biogerontology, 4,Suppl. 1, 89 (2003).

    Google Scholar 

  14. 14.

    R. Weindruch, K. P. Keenan, J. M. Carney, et al., J. Gerontol. Biol. Sci., 56 A, Special Issue 1, 20–33 (2001).

    Google Scholar 

Download references

Author information



Corresponding author

Correspondence to V. N. Anisimov.

Additional information


Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 139, No. 6, pp. 691–694, June, 2005

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Anisimov, V.N., Egormin, P.A., Bershtein, L.M. et al. Metformin Decelerates Aging and Development of Mammary Tumors in HER-2/neu Transgenic Mice. Bull Exp Biol Med 139, 721–723 (2005).

Download citation

Key Words

  • metformin
  • life span
  • breast cancer
  • transgenic mice
  • HER-2/neu